rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PLSE
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      All You Need to Know About Pulse Biosciences (PLSE) Rating Upgrade to Buy
      11h agoYahoo FinancePLSE
      Needham reiterates Pulse Biosciences stock rating on thyroid trial
      Nov 17Investing.comPLSE
      Pulse Biosciences at stifel 2026 healthcare conference: afib push builds
      Nov 12Investing.comPLSESF
      Pulse Biosciences stock hits all-time high at 58.94 USD
      Nov 9Investing.comPLSE
      Pulse Biosciences Inc (PLSE) Q3 2026 Earnings Call Highlights: NanoPulse AF Study Enrollment ...

      Pulse Biosciences Inc (PLSE) wrapped up enrollment in its NanoPulse AF pivotal IDE study three months early while reporting a wider GAAP net loss of $23.1 million and roughly two years of cash runway.

      Nov 6Yahoo FinancePLSE
      What Pulse Biosciences (PLSE) Said on Its Q3 Earnings Call
      Nov 6Yahoo FinancePLSE
      Pulse Biosciences reports interim thyroid nodule study results
      Nov 6Investing.comPLSE
      Mizuho raises Pulse Biosciences stock price target on trial progress
      Nov 6Investing.comPLSE
      Pulse Biosciences, Inc (PLSE) Reports Q3 Loss, Misses Revenue Estimates
      Nov 6Yahoo FinancePLSE
      Pulse Biosciences Q3 2026 Earnings Call Transcript
      Nov 5BenzingaPLSE
      Pulse Bio (PLSE) Q3 2026 Earnings Call Transcript
      Nov 5The Globe and MailPLSE
      Pulse Biosciences (PLSE) Stock Still Seems Rich Against Book Value
      Oct 25Yahoo FinancePLSE
      Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

      HAYWARD, Calif., October 22, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates and financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will host a corresponding conference call to discuss business updates beginning at 1:30pm PT / 4:30pm ET.

      Oct 22Yahoo FinancePLSE
      Pulse Biosciences (PLSE) Stock Fair Value Rises After Analyst Target Increases
      Oct 17Yahoo FinancePLSE
      Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
      Oct 14Yahoo FinancePLSE
      Pulse Biosciences' 2027 Trial Readout Crucial to Evaluate New Pulsed Field Ablation Modality, Oppenheimer Says
      Oct 13Yahoo FinancePLSEOPY
      Oppenheimer Adjusts Price Target on Pulse Biosciences to $60 From $35, Keeps Outperform Rating

      Pulse Biosciences (PLSE) has an average rating of buy and mean price target of $62.33, according to

      Oct 13Yahoo FinancePLSE
      Oppenheimer raises Pulse Biosciences price target on competitor issues
      Oct 13Investing.comPLSE
      Why Pulse Biosciences (PLSE) Is Up 12.3% After Full NANOPULSE-AF Enrollment And nPulse Spotlight

      Pulse Biosciences recently announced that its pivotal NANOPULSE-AF Study has reached full enrollment of 164 evaluable patients across 15 sites, and its latest nPulse technology for ventricular arrhythmias was featured at the now-completed 21st Annual International Ventricular Arrhythmias Symposium in New York. Together, these updates highlight growing clinical and physician engagement around the nPulse platform, potentially strengthening the company’s position in emerging pulse field...

      Oct 10Yahoo FinancePLSE
      Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Oct 9Yahoo FinancePLSE
      Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026

      HAYWARD, Calif., October 08, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the latest nPulse™ technology advancement will be featured during the 21st Annual International Ventricular Arrhythmias (VT) Symposium 2026, taking place October 9-10 in New York.

      Oct 8Yahoo FinancePLSE
      Pulse Biosciences completes enrollment in cardiac ablation study
      Oct 7Investing.comPLSE
      Pulse Biosciences Reaches Enrollment Target in Nanopulse-AF Study
      Oct 7Yahoo FinancePLSE
      Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
      Oct 7Yahoo FinancePLSE
      Canaccord raises Pulse Biosciences stock price target on tech potential
      Oct 6Investing.comPLSE
      Pulse Biosciences (PLSE) Stock Fair Value Rises After Analysts Back NsPFA Data

      The fair value estimate for Pulse Biosciences has shifted from US$45.25 to US$54.00 per share, which is about a 19% move in the underlying price target framework. Analysts link this change to fresh enthusiasm around the company’s nsPFA technology, first in human European data, and upcoming clinical and regulatory milestones that could influence how investors frame long term potential. In the sections that follow, you will see how these factors shape the current narrative and how to track it...

      Oct 3Yahoo FinancePLSE
      Pulse Biosciences: Promising Technology, But Hard To Justify Its Valuation (NASDAQ:PLSE)

      PLSE’s catheter data and rapid pivotal enrollment showcase that they have a healthy and promising business. I reiterate my “Hold” on PLSE at these levels.

      Sep 27Seeking AlphaPLSE
      BTIG initiates Pulse Biosciences stock coverage with buy rating
      Sep 23Investing.comPLSE
      BTIG Initiates Pulse Biosciences at Buy With $70 Price Target

      Pulse Biosciences (PLSE) has an average rating of buy and mean price target of $54, according to ana

      Sep 23Yahoo FinancePLSE
      Pulse Biosciences Launches New ATM Equity Program

      Detailed price information for Pulse Biosciences CS (PLSE-Q) from The Globe and Mail including charting and trades.

      Sep 16The Globe and MailPLSE
      Pulse Biosciences Completes Enrollment in PRECISE-BTN Study

      Detailed price information for Pulse Biosciences CS (PLSE-Q) from The Globe and Mail including charting and trades.

      Sep 16The Globe and MailPLSE
      Pulse Biosciences enters $85 million equity distribution agreement with Mizuho
      Sep 15Investing.comPLSE
      Pulse Biosciences completes enrollment in thyroid nodule study
      Sep 15Investing.comPLSE
      Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

      HAYWARD, Calif., September 15, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced two milestones in the PRECISE-BTN clinical study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules (BTNs). The first patient enrolled in the study completed the final 12-month follow-up visit in August at Sara

      Sep 15Yahoo FinancePLSE
      Pulse Biosciences Completes Enrollment in 100-Patient Thyroid Nodule Study
      Sep 15Yahoo FinancePLSE
      Why is Pulse Biosciences stock surging today?
      Sep 10Investing.comPLSE
      Analysts Are Bullish on These Healthcare Stocks: Agilent (A), AbSci (ABSI)

      Detailed price information for Pulse Biosciences CS (PLSE-Q) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailABSIPLSE
      Why Pulse Biosciences Stock Popped Today | The Motley Fool

      The medical device maker now has a new bull touting its growth potential.

      Sep 10The Motley FoolPLSE
      Why Pulse Biosciences Stock Popped Today

      The medical device maker now has a new bull touting its growth potential.

      Sep 9Yahoo FinancePLSE
      Pulse Biosciences stock hits all-time high at 56.15 USD
      Sep 9Investing.comPLSE
      Freedom Capital initiates Pulse Biosciences stock with buy rating
      Sep 9Investing.comPLSE
      Pulse Biosciences COO Liane Teplitsky buys $99,971 in stock
      Sep 2Investing.comPLSE
      Pulse Biosciences stock hits all-time high at 51.0 USD
      Sep 1Investing.comPLSE
      Pulse Biosciences COO Liane Teplitsky buys $99,965 in stock
      Aug 29Investing.comPLSE
      Top 3 Health Care Stocks That May Keep You Up At Night In Q3 - Veeva Systems (NYSE:VEEV), Pulse Bioscienc

      As of Aug. 27, 2026, three health care stocks are overbought and could be giving a real warning to momentum investors, according to the RSI indicator.

      Aug 27BenzingaPLSEVEEV
      Pulse Biosciences stock hits all-time high at 48.92 USD
      Aug 21Investing.comPLSE

      This is the newest page. Registered accounts read further back.